<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709485</url>
  </required_header>
  <id_info>
    <org_study_id>0094-17CTIL</org_study_id>
    <nct_id>NCT03709485</nct_id>
  </id_info>
  <brief_title>Evaluation of Gut Microbiome in Patients With Prostate Cancer</brief_title>
  <official_title>Analysis of Gut Microbiome in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research will focus on the possible connection between prostate cancer, and various
      species of bacteria in the large intestine. In consecutive patients, referred to prostate
      biopsies, rectal swabs will be taken before the biopsies and before antibiotic treatment. The
      gut flora will be examined and characterized by a microbiome analysis tool. Negative patients
      will serve as internal control. The investigators will look for association between prostate
      cancer of various grades and the presence of specific enteropathogens in the rectal flora of
      the participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is the no. 1 cancer among men. Risk factors include Afro-American origin,
      prostate cancer in a first degree relatives and the presence of BRCA2 genetic mutations. No
      specific association has been described yet between prostate cancer and specific gut
      bacteria.

      The GI tract is the home of billions of bacteria. The microbiome functions as a separate
      organ and contains 10 times the amount of genes compared to the human genome. The microbiome
      has crucial impact on the human metabolism, inflammatory processes and filtration of GI
      content. All of these effects may contribute to the exposure of the human body to various
      carcinogens and inflammatory factors, leading eventually to the development of cancer in
      remote organs.

      The purpose of this research is to try and identify specific species that might be related to
      the development of prostate cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of gut microbiome</measure>
    <time_frame>1 year</time_frame>
    <description>Analysis of rectal swab cultures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of prostate cancer patients and specific microbes.</measure>
    <time_frame>1 year</time_frame>
    <description>Relationship between patients with prostate cancer and specific strains of rectal microbes</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>prostate biopsy patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rectal swab for microbial culture.</intervention_name>
    <description>Rectal swab and culture.</description>
    <arm_group_label>prostate biopsy patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male gender

          -  age above 45

          -  referred for prostate biopsy

        Exclusion Criteria:

          -  age below 45

          -  antimicrobial therapy in the 7 days prior to biopsy

          -  previous prostate or pelvic irradiation

          -  patients who suffer from inflammatory bowel disease

          -  systemic chemotherapy for any reason in the 3 months prior to the biopsy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>males</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ran Katz, MD</last_name>
    <phone>+972-4-6828775</phone>
    <email>ran.k@ziv.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Talia Simchi</last_name>
    <phone>+972-4-6828775</phone>
    <email>Tali.s@ziv.health.gov.il</email>
  </overall_contact_backup>
  <reference>
    <citation>Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D, Shah DP. Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. Eur Urol. 2018 Nov;74(5):575-582. doi: 10.1016/j.eururo.2018.06.033. Epub 2018 Jul 12.</citation>
    <PMID>30007819</PMID>
  </reference>
  <reference>
    <citation>Golombos DM, Ayangbesan A, O'Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, Scherr DS. The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. Urology. 2018 Jan;111:122-128. doi: 10.1016/j.urology.2017.08.039. Epub 2017 Sep 6.</citation>
    <PMID>28888753</PMID>
  </reference>
  <reference>
    <citation>Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):345-354. doi: 10.1038/s41391-018-0041-1. Epub 2018 May 23. Review.</citation>
    <PMID>29795140</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

